公开(公告)号：US20200039957A1

公开(公告)日：2020-02-06

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Kazuaki TAKAMI ,  Norihito TOKUNAGA ,  Tomohiro OKAWA ,  Akita SHIBUYA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA

IPC: C07D401/12 ,  C07D211/22 ,  C07D401/14 ,  C07C59/72 ,  C07D213/64 ,  C07D401/10 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20160115128A1

公开(公告)日：2016-04-28

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei AIDA ,  Yayoi YOSHITOMI ,  Yuko HITOMI ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Hideki FURUKAWA ,  Akito SHIBUYA ,  Koji WATANABE ,  Yasufumi MIYAMOTO ,  Tomohiro OKAWA ,  Nobuyuki TAKAKURA ,  Seiji MIWATASHI

IPC: C07D211/34 ,  C07D413/10 ,  C07D401/14 ,  C07D405/12 ,  C07D413/14 ,  C07D401/10 ,  C07D401/12

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Abstract translation: 提供具有GPR40激动剂活性和GLP-1促分泌作用的新型芳环化合物。 由下式表示的化合物：其中每个符号如说明书所述，或其盐具有GPR40激动剂活性和GLP-1促分泌素作用，可用于预防或治疗癌症，肥胖症，糖尿病，高血压， 高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症等，具有优异的疗效。

公开(公告)号：US20230134307A1

公开(公告)日：2023-05-04

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20190300536A1

公开(公告)日：2019-10-03

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  C07D471/04 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20190125728A1

公开(公告)日：2019-05-02

申请号：US16089548

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei IKEDA ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: A61K31/4188 ,  A61K31/407 ,  A61K31/454 ,  A61K31/496 ,  A61P25/16 ,  A61P25/08 ,  A61P25/24 ,  A61P25/28 ,  A61P21/00

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20210332053A1

公开(公告)日：2021-10-28

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20160318864A1

公开(公告)日：2016-11-03

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki KOIKE ,  Makoto FUSHIMI ,  Jumpei AIDA ,  Shuhei IKEDA ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Hidekazu TOKUHARA

IPC: C07D207/273 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12 ,  C07D403/14 ,  C07D417/14 ,  C07D413/12 ,  C07D471/04 ,  C07D401/14 ,  C07D417/12 ,  C07D405/12

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20150018373A1

公开(公告)日：2015-01-15

申请号：US14325564

申请日：2014-07-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hideyuki IGAWA ,  Masashi TAKAHASHI ,  Keiko KAKEGAWA ,  Minoru IKOMA ,  Jumpei AIDA

IPC: C07D401/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14 ,  C07D409/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 提供具有黑色素浓集激素受体拮抗作用的化合物，并且可用作预防或治疗肥胖症等的药剂。 由式（I）表示的化合物或其盐，其中每个符号如说明书中所定义。

公开(公告)号：US20230150934A1

公开(公告)日：2023-05-18

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20230002318A1

公开(公告)日：2023-01-05

申请号：US17755907

申请日：2020-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  C07D401/06 ,  A61P25/18

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.